57 results about "Antineoplastic Immunotherapeutic" patented technology

The invention relates to a drug and a tumor whole-cell vaccine for treating or preventing tumor, and preparation methods and applications of the drug and the whole-cell vaccine, and belongs to the fields of bioengineering and biological immunology. The invention provides a drug with good effect for treating or preventing tumor and a tumor whole-cell vaccine. The drug comprises the tumor whole-cell vaccine, a cation liposome, and recombinant plasmid for encoding interleukin-15 gene. The drug has the dual actions of tumor prevention immunization and anti-tumor immune treatment, and has durable action and obvious tumor prevention or treatment effect.

The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody / cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.

The invention provides a method for preventing tumor-induced T cell aging and reversing immunosuppression capability of the tumor-induced T cell. A ligand of a TOLL like receptor 8 is provided to a cell; a TOLL like receptor 8 (TLR8) signal channel in a tumor cell is activated; the tumor-induced T cell aging is blocked up, so as to improve the antitumor immunity. The ligand of the TOLL like receptor 8 is characterized by being oligonucleotides and comprising adenine, guanine, a main chain connecting bond for connecting the guanine and nuclease resistance residue of adjacent nucleic acid bases (preferably a chemical bond is phosphorothioate); a nucleic acid synthesis sequence is 5'-AGG...GA-3'; G represents guanine; A represents adenine; G and G are modified by a dithio phosphate ester bond; the number of G may be 3 to10 in difference; an acid synthesis sequence of a common ligand Poly-G3 is 5'-AGGGA-3'. By injecting TLR8 ligand Poly-G3 into the tumor, the inhibitory effect of a CD8<+>T cell can be significantly enhanced.

The invention relates to a prognosis prediction model for squamous cell carcinoma and application thereof. The prognosis prediction model is composed of biomarkers CFLAR, RGS19, PINK1, CTSD and related solutions. The invention also comprises application of a reagent for detecting the expression quantity of the biomarkers in preparation of a kit for evaluating the anti-tumor immunotherapy reactivity and prognosis survival of squamous cell carcinoma. According to the invention, screening and construction are carried out after whole transcriptome sequencing and machine learning of squamous cell carcinoma samples of large-sample anti-tumor immunotherapy, so that the reactivity of squamous cell carcinoma patients in anti-tumor immunotherapy can be efficiently and accurately predicted, effective guidance is provided for clinicians to make treatment decisions on squamous cell carcinoma patients, and the occurrence of invalid treatment is reduced, thereby reducing the treatment cost and discomfort experience of patients.

The invention discloses a pharmaceutical composition nano-system for anti-tumor immunotherapy, and particularly, a therapeutically effective amount of one or more perfluorocarbon compounds and one ormore immune checkpoint inhibitors are wrapped in an albumin shell as active ingredients. It is proved by experiments that a pharmaceutical composition can increase the vascular permeability by openinga tumor vascular barrier, promotes the infiltration of immune T cells in tumors, enhances the killing activity of tumor-associated T cells at the same time, increases the expression level of toxic killer factors such as IFN-gamma, TNF-alpha and IL-6, exerts a synergistic effect of anti-tumor immunity, and provides a solution to the problem of low patient response rate in the clinical single druguse process of the immune checkpoint inhibitors.

The invention provides application of p62 / SQSTM1 as a biomarker and a target site detection reagent as well as application of an inhibitor of p62 / SQSTM1 in PD-L1 / PD-1 monoclonal antibody tumor immunotherapy Drug, and also discloses application of combination of sunitinib and CTLA-4 monoclonal antibody drugs in preparation of tumor immunotherapy adjuvant drugs, wherein the tumor is preferably melanoma or lung cancer. The invention provides a new research and development direction of PD-L1 / PD-1 monoclonal antibody tumor immunodetection or immunotherapy adjuvant drugs, and develops a new drug combination mode.

The invention provides an application of ADORA1 in preparation of a PD-L1 / PD-1 monoclonal antibody tumor immunotherapy drug, specifically relates to an application of ADORA1 as a biomarker to PD-L1 / PD-1 monoclonal antibody tumor immunotherapy before medication, or an application of ADORA1 as a target site detection reagent in preparation of the PD-L1 / PD-1 monoclonal antibody tumor immunotherapy drug, and an application of combination of an ADORA1 inhibitor and the PD-L1 / PD-1 monoclonal antibody drug in preparation of a tumor immunotherapy adjuvant drug. The tumor is a solid tumor, preferably melanoma or lung cancer, and further preferably melanoma or non-small cell lung cancer.

The present invention discloses a recombinant superantigen staphylococcal enterotoxin B (SEB) mutant, and a preparation method and applications thereof. According to the present invention, a SEB genome derived from natural staphylococcus aureus is extracted, and after the SEB genome is obtained, site-specific mutagenesis at toxicity-related amino acid sites is performed to obtain the SEB mutant. The SEB mutant has characteristics of both enhanced activity and weakened toxicity, and can be used as anti-tumor immune therapy drugs or immune system modulating drugs. The recombinant superantigen SEB mutant has good market prospects.

The invention provides an application of a DPCPX inhibitor in preparation of a PD-L1 / PD-1 monoclonal antibody tumor immunotherapy drug, specifically, the DPCPX inhibitor is used for preparing the PD-L1 / PD-1 monoclonal antibody tumor immunotherapy drug by targeted inhibition of an adenosine receptor ADORA1, and also provides an application of combination of the DPCPX inhibitor and the PD-L1 / PD-1 monoclonal antibody drug in preparation of a tumor immunotherapy adjuvant drug. The invention also provides an application of ATF3 as a target site detection reagent in combination with the DPCPX inhibitor in preparation of the PD-L1 / PD-1 monoclonal antibody tumor immunotherapy drug. The tumor is a solid tumor, preferably melanoma or lung cancer, and further preferably melanoma or non-small cell lung cancer.

The invention provides an application of ATF3 as a target site detection reagent in preparation of a PD-L1 / PD-1 monoclonal antibody tumor immunotherapy drug, an application of ATF3 as the target sitedetection reagent combined with a DPCPX inhibitor in the preparation of the PD-L1 / PD-1 monoclonal antibody tumor immunotherapy drug, and an application of ADORA1-ATF3 as the target site detection reagent in the preparation of the PD-L1 / PD-1 monoclonal antibody tumor immunotherapy drug. The tumor is a solid tumor, preferably melanoma or lung cancer, and further preferably melanoma or non-small celllung cancer.

The invention discloses a PD-1 targeted blocking peptide and an application thereof, and belongs to the field of antitumor immunity treatment. A phage display technique is adopted for obtaining the blocking peptide for specially targeting PD-1, and the sequence of the blocking peptide is shown as SEQID NO.1. Phages are used for showing a 12-peptide library, and through four-round biological elutriation, phage monoclonal antibodies which have specificity affinity interaction with PD-1 protein are obtained and can target tumor cells naturally expressing PD-1; through sequencing, a polypeptide sequence shown on the surfaces of the phages can be obtained; and is chemically synthesized so that the polypeptide sequence is proved to be capable of adjusting human PBMC to secrete cell factors IFN-gamma and IL-2; and the PD-1 blocking peptide is entrapped, so that nanoparticles are prepared. In-vivo drug effect experiment verifies that the PD-1 targeted blocking peptide has notable antitumor effects. The PD-1 targeted blocking peptide can realize specific binding with the PD-1, combination of PD1 and PD-L1 can be blocked, and the functions of T cells can be restored. The targeted blocking peptide can be widely applied to the fields of tumor targeting, immunomodulation and tumor resistance.

The invention discloses a preparation method of fluorinated polyamide amine and application thereof serving as a vaccine immune adjuvant. The preparation method includes following steps: dissolving polyamide amine and heptafluobutryric anhydride into an organic solvent to obtain a mixed solution I; adding triethylamine into the mixed solution I, stirring for reaction, and performing dialysis and freeze-drying after reaction is finished to obtain fluorinated polyamide amine. Heptafluobutryric anhydride is used to modify polyamide amine, so that prepared fluorinated polyamide amine has positivecharge in neutral pH environment, antigen ovalbumin can be wrapped through electrostatic attraction to form a nano preparation with the positive charge, and the preparation can effectively promote intracellular release of antigen protein and cytoplasm delivery. Therefore, fluorinated polyamide amine prepared by the method can serve as a vaccine delivery system to induce cellular immunological response so as to realize effective antitumor immunotherapy.

The invention relates to an application of fullerene nanoparticles in preparation of a drug for tumor immunotherapy. The fullerene nanoparticles comprise an amino acid modified fullerene water-solublemodifier; the drug can activate immune cells, polarize tumor-associated macrophages and / or improve T lymphocyte infiltration at a tumor site; and the treatment effect of an antitumor immunity drug PD-L1 inhibitor is enhanced.

The invention discloses a conditioning medicine aiming at pain and rheumatism and a preparation method of the conditioning medicine. The conditioning medicine consists of the following components in percentage by weight: 20-40 percent of coriolus versicolor mycelium polysaccharide, 15-30 percent of needle mushroom mycelium polysaccharide, 20-35 percent of polygahatous polysaccharide and 15-35 percent of rheum officinale polysaccharide. The preparation method comprises the following steps: respectively extracting the coriolus versicolor mycelium polysaccharide, needle mushroom mycelium polysaccharide, polygahatous polysaccharide and rheum officinale polysaccharide, and preparing according to the ratio. The conditioning medicine disclosed by the invention is low in cost and does not have any toxic or side effect, can achieve the effects of improving the human immunologic function, relieving swelling and pain, diminishing inflammation, expelling wind and eliminating dampness and diminishing inflammation and relieving pain and has obvious effects on traumatic injury, lumbar muscle degeneration, sciatica, prosopalgia, facial palsy and spasticity, rheumatoid arthritis, antitumor immunological therapy, internal and external hemorrhoids and colitis. The conditioning medicine is taken by adults 2-3 times per day, 1-2 grains of the medicine are taken each time, and the medicine can be taken for a long time.

The invention relates to an amphipathic phosphorus-containing crown macromolecular material as well as preparation and application thereof. The structure of the amphipathic phosphorus-containing crown macromolecular material is represented by a formula I in the specification. The raw materials are commercialized, the preparation method is simple and easy to operate, and the prepared nano-composite can cause death of immunogenic tumor cells to increase the proportion of cytotoxic T cells on one hand, and can promote proliferation of natural killer cells in vivo on the other hand, so that the aims of remodeling a tumor microenvironment and enhancing anti-tumor immunotherapy are achieved, and good application prospects are realized in the field of tumor treatment.

The invention relates to the field of tumor treatment, in particular to application of dulatide in preparation of anti-tumor drugs. The invention discloses the effect of dulatide in the aspect of immune activation and the effect of dulatide in the aspect of anti-tumor immune activation. The invention further discloses the effect of the dulatide in the aspect of anti-tumor immunotherapy. Results of the invention show that dulatide can significantly stimulate immune cell proliferation, and can significantly stimulate release of interferon gamma (IFN-gamma); on a plurality of in-vivo animal tumor-bearing models, dulatide can significantly inhibit tumor growth and significantly prolong the lifetime of tumor-bearing mice; the dulaglycopeptide can obviously prolong the lifetime of mice after metastatic and recurrent tumor operation, and the dulaglycopeptide is a drug on the market, so that the safety of the dulaglycopeptide is basically guaranteed. In short, the dulatide can be used for preparing antitumor drugs.

The invention relates to a marker for evaluating anti-tumor immunotherapy responsiveness and prognosis survival of advanced bladder cancer and application of the marker. The marker consists of the following six genes: CDH18, CXCL10, FOXN4, SLC6A4, CXCL9 and PCDH11X. The invention further comprises application of a reagent for detecting the expression quantity of the marker in preparation of a kitfor evaluating responsiveness and prognosis survival of advanced bladder cancer anti-tumor immunotherapy. According to the invention, full transcriptome sequencing is carried out on advanced bladder cancer specimens based on large-sample anti-tumor immunotherapy, and screening and construction are carried out after machine learning, so that the reactivity of the advanced bladder cancer patients receiving the anti-tumor immunotherapy can be efficiently and accurately predicted; effective guidance opinions can be provided for clinicians to make treatment decisions on patients with advanced bladder cancer, invalid treatment is reduced, and therefore the treatment cost and discomfort experience of the patients are reduced.

The invention discloses a novel targeted drug delivery system of an antibody synthetic bacterium-nano stimulant heterozygote and application of the novel targeted drug delivery system in the field of anti-tumor immunotherapy, and particularly discloses a pH response copolymer, a nano stimulant, an antibody synthetic bacterium and an antibody synthetic bacterium-nano stimulant heterozygote system as well as a preparation method and application of the system.

The invention belongs to the fields of molecular biology and gene engineering, and relates to tumor antigen NY-ESO-1 protein originated from rhesus monkeys, coding gene, and applications thereof. The mentioned rhesus monkey NY-ESO-1 protein can be used for preparing antitumor vaccines, the gene which codes the NY-ESO-1 protein can be used for preparing antitumor nucleic acid vaccine; the antitumor vaccine or nucleic acid vaccine mentioned above can be merged into one or more cell factors or microbial components such as granular leukocyte-macrophage colony stimulating factor, gamma interferon, interleukin 2, transforming growth factor beta4 to made into immunity auxiliary agents; and the rhesus monkey NY-ESO-1 protein can be used with tumor-testicle antigen to have a combined immunization function or be made into polyvalent subunit vaccines. Furthermore, the invention also provides an immunogenicity composition or vaccine, and provides a novel method, which has a wide application prospect, for tumor immunity treatment.

Disclosed herein are methods for treating solid mass tumors with direct delivery of an anti-tumor immunotherapeutic agent to the tumor site. In one aspect, this invention encompasses methods of treating solid mass tumors by direct microinjection via a microcatheter of an anti-tumor immunotherapeutic agent into the microvasculature leading into tumor thereby providing high levels of contact with the tumor while minimizing the degree of systemic buildup of the immunotherapeutic agent.

The invention provides an antigen and adjuvant co-delivery nano vaccine based on protamine as a carrier. The nano vaccine comprises a carrier, an antigen and an adjuvant, wherein the carrier is protamine sulfate; The invention also provides a preparation method and application of the vaccine. The nano vaccine prepared by the invention can effectively improve uptake efficiency of antigen presentingcells on antigens and adjuvants, efficiently stimulate maturation of the antigen presenting cells, assist the antigens in realizing cross presentation, significantly improve in-vivo transfer efficiency of the antigens and the adjuvants, stimulate a body to produce high-efficiency humoral immunity and cellular immunity, and at the same time produce an immune memory effect. In-vivo treatment is carried out on mouse subcutaneous melanoma, and it is proved that the nano vaccine has a good anti-tumor immunotherapy effect. The nano vaccine is simple in structure, convenient to prepare and excellentin immunotherapy performance, and has good application potential.

The invention discloses a human serum albumin nano-drug (IDNPs) based on a metabolic checkpoint as well as a preparation method and an application of the human serum albumin nano-drug. A prodrug molecule IDOi-DON obtained by coupling an indoleamine-2, 3-dioxygenase inhibitor (IDOi) and a metabolic reprogramming agent DON through a chemical bond amidation reaction can be subjected to enzymolysis breakage in a tumor microenvironment, and is externally coated with natural biocompatible serum albumin, so that the stability of the drug can be improved, the toxic and side effects of the drug can be reduced, the drug is enriched at a tumor site, and the drug activity is improved. Through the synergistic effect of the two drugs, the effects of inhibiting IDO activity of tumor cells, inhibiting Treg cell proliferation and activating CD8 + T cells can be achieved, and the anti-tumor immunotherapy effect can be synergistically enhanced.

The disclosure provides a composition for inhibiting the growth and / or invasion of tumor cells, an enhancer of an anti-tumor effect of a drug for the purpose of removing immunosuppression caused by cancer, or the like, which is characterized by being used for a specific subject.

The invention relates to a cationic liposome vaccine as well as a preparation method and application thereof. A fusion protein of an immunologic adjuvant and an antigen peptide, particularly a fusion protein of recombinant trichosanthin and legumain polypeptide, is entrapped in a cationic liposome to prepare the cationic liposome vaccine. Experiments prove that after local immunization is carried out on a mouse by using the liposome vaccine, on one hand, APCs can be effectively recruited, lymph node targeting can be realized through a size effect of nanoparticles, APCs in lymph nodes are sensitized, and recognition and presentation of antigens are promoted, so that activation and proliferation of antigen-specific T cells are promoted; and on the other hand, the TAM and the tumor immune microenvironment are regulated and controlled to promote the inhibitory microenvironment to realize'immune normalization ', so that the anti-tumor immunotherapy effect is achieved.

Water soluble compounds having a furoxan structure which are capable of inhibiting metabolic pathways involved in the development of the tumours are provided. The use of such compounds as a medicament in the therapy of the tumours and as an adjuvant in the immunotherapy protocols against neoplasms is also described.